CD4 and neoplasm: Research in cancer immunotherapy has mainly focused on CD8+ T cells in the tumor microenvironment (TME), However, it has been reported that antitumor immunity cannot be induced unless the tumor cells have the MHC class II binding neoantigens, which are recognized by CD4+ T cells.